which is an inhaled inhibitor of galectin-3. Since then the US drugmaker has bolstered its early-stage research in fibrosis via academic partnerships with the California Institute for Biomedical ...

Galectin Therapeutics is dedicated to developing ... the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development ...

Geneos Wealth Management Inc. raised its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 10.2% in the 4th ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Galectin Therapeutics is dedicated to developing novel therapies ... the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug ...